Trial · NCT00544908
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
NCT00544908, Phase 2, Terminated, City of Hope Medical Center; results first posted 2015-09-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Treating Patients With Stage IV Pancreatic Cancer. Trials, record NCT00544908. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00544908
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
- NCT number
- NCT00544908
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- City of Hope Medical Center
- Conditions
- Pancreatic Cancer
- Interventions
- dasatinib, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, quality-of-life assessment
- First posted
- 2007-10-16
- Last updated
- 2015-10-05
- Results first posted
- 2015-09-17
- Limitations and caveats
- Study was terminated early due to toxicity.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) Rate at 4 Months | Four months. | Progressive disease - appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of non-target lesions only is exceptional, in such circumstances, the opinion of the treating physician should prevail and the progression status should be confirmed later on by a review panel (or study chair/primary investigator). |
| Secondary | Response Rate | After every two cycles, up to 5 years | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) Rate at 4 Months | Four months. | percentage of participants | NUMBER | |
| SECONDARY | Response Rate | After every two cycles, up to 5 years | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) Rate at 4 Months | Dasatinib | 0 | percentage of participants | ||
| Response Rate | Dasatinib | 0 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dasatinib | 7 | |
| Overall Study | COMPLETED | Dasatinib | 7 | |
| Overall Study | NOT COMPLETED | Dasatinib | 0 |
Source ClinicalTrials.gov
Adverse events56
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Dasatinib | 5 | 7 | 6 |
| other | Sinus bradycardia | Cardiac disorders | Dasatinib | 1 | 7 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Dasatinib | 1 | 7 | 1 |
| other | Vitreous hemorrhage | Eye disorders | Dasatinib | 1 | 7 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Dasatinib | 2 | 7 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Dasatinib | 5 | 7 | 5 |
| other | Constipation | Gastrointestinal disorders | Dasatinib | 2 | 7 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib | 1 | 7 | 1 |
| other | Dry mouth | Gastrointestinal disorders | Dasatinib | 1 | 7 | 1 |
| other | Flatulence | Gastrointestinal disorders | Dasatinib | 1 | 7 | 2 |
1 to 10 of 56Source ClinicalTrials.gov
See all 56 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib | ||
| Total, other adverse events | Dasatinib | 6 | 7 |
| Total, serious adverse events | Dasatinib | 2 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA033572 | Cancer Center Support Grant | CARPTEN, JOHN D. | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00544908
GET https://conductscience.org/api/trials/v1/NCT00544908/events?page=2